← All trials
NCT03278470
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2017
- Primary completion
- Mar 19, 2018
- Completion date
- Mar 19, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hanlim Pharm. Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.